Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1983 1
1989 1
1991 1
1992 1
1993 1
1994 1
1995 4
1996 5
1997 4
1998 5
1999 2
2000 3
2001 2
2002 5
2003 3
2004 7
2005 3
2006 4
2007 10
2008 8
2009 8
2010 8
2011 5
2012 7
2013 8
2014 5
2015 9
2016 4
2017 14
2018 19
2019 14
2020 10
2021 21
2022 26
2023 10

Text availability

Article attribute

Article type

Publication date

Search Results

223 results

Results by year

Filters applied: . Clear all
Page 1
Empagliflozin in Patients with Chronic Kidney Disease.
The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. The EMPA-KIDNEY Collaborative Group, et al. N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4. N Engl J Med. 2023. PMID: 36331190 Free PMC article. Clinical Trial.
Dapagliflozin in Patients with Chronic Kidney Disease.
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Heerspink HJL, et al. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24. N Engl J Med. 2020. PMID: 32970396 Free article. Clinical Trial.
Avacopan for the Treatment of ANCA-Associated Vasculitis.
Jayne DRW, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group. Jayne DRW, et al. N Engl J Med. 2021 Feb 18;384(7):599-609. doi: 10.1056/NEJMoa2023386. N Engl J Med. 2021. PMID: 33596356 Clinical Trial.
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK; HERCULES Investigators. Scully M, et al. N Engl J Med. 2019 Jan 24;380(4):335-346. doi: 10.1056/NEJMoa1806311. Epub 2019 Jan 9. N Engl J Med. 2019. PMID: 30625070 Free article. Clinical Trial.
Ferroptosis and Necroptosis in the Kidney.
Belavgeni A, Meyer C, Stumpf J, Hugo C, Linkermann A. Belavgeni A, et al. Among authors: hugo c. Cell Chem Biol. 2020 Apr 16;27(4):448-462. doi: 10.1016/j.chembiol.2020.03.016. Cell Chem Biol. 2020. PMID: 32302582 Free article. Review.
Dexamethasone sensitizes to ferroptosis by glucocorticoid receptor-induced dipeptidase-1 expression and glutathione depletion.
von Mässenhausen A, Zamora Gonzalez N, Maremonti F, Belavgeni A, Tonnus W, Meyer C, Beer K, Hannani MT, Lau A, Peitzsch M, Hoppenz P, Locke S, Chavakis T, Kramann R, Muruve DA, Hugo C, Bornstein SR, Linkermann A. von Mässenhausen A, et al. Among authors: hugo c. Sci Adv. 2022 Feb 4;8(5):eabl8920. doi: 10.1126/sciadv.abl8920. Epub 2022 Feb 2. Sci Adv. 2022. PMID: 35108055 Free PMC article.
Dysfunction of the key ferroptosis-surveilling systems hypersensitizes mice to tubular necrosis during acute kidney injury.
Tonnus W, Meyer C, Steinebach C, Belavgeni A, von Mässenhausen A, Gonzalez NZ, Maremonti F, Gembardt F, Himmerkus N, Latk M, Locke S, Marschner J, Li W, Short S, Doll S, Ingold I, Proneth B, Daniel C, Kabgani N, Kramann R, Motika S, Hergenrother PJ, Bornstein SR, Hugo C, Becker JU, Amann K, Anders HJ, Kreisel D, Pratt D, Gütschow M, Conrad M, Linkermann A. Tonnus W, et al. Among authors: hugo c. Nat Commun. 2021 Jul 20;12(1):4402. doi: 10.1038/s41467-021-24712-6. Nat Commun. 2021. PMID: 34285231 Free PMC article.
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NefIgArd Trial Investigators. Barratt J, et al. Kidney Int. 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19. Kidney Int. 2023. PMID: 36270561 Free article. Clinical Trial.
The pathological features of regulated necrosis.
Tonnus W, Meyer C, Paliege A, Belavgeni A, von Mässenhausen A, Bornstein SR, Hugo C, Becker JU, Linkermann A. Tonnus W, et al. Among authors: hugo c. J Pathol. 2019 Apr;247(5):697-707. doi: 10.1002/path.5248. Epub 2019 Feb 25. J Pathol. 2019. PMID: 30714148 Review.
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O; REPRISE Trial Investigators. Torres VE, et al. N Engl J Med. 2017 Nov 16;377(20):1930-1942. doi: 10.1056/NEJMoa1710030. Epub 2017 Nov 4. N Engl J Med. 2017. PMID: 29105594 Free article. Clinical Trial.
223 results